Aligos Gross Profit from 2010 to 2024

ALGS Stock

USD 25.51 2.52 10.96%

Aligos Therapeutics Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Aligos Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

12.5 M

Current Value

13.1 M

Quarterly Volatility

6.8 M

Credit Downgrade

Yuan Drop

Covid

Check Aligos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aligos Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 834.8 K, Net Interest Income of 1.3 M or Interest Income of 1 M, as well as many indicators such as Price To Sales Ratio of 25.26, Dividend Yield of 0.0 or PTB Ratio of 4.71. Aligos financial statements analysis is a perfect complement when working with Aligos Therapeutics Valuation or Volatility modules.

Check out the analysis of Aligos Therapeutics Correlation against competitors.

For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.

Latest Aligos Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Aligos Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Aligos Therapeutics minus its cost of goods sold. It is profit before Aligos Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Aligos Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aligos Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (71.17 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Aligos Gross Profit Regression Statistics

	Arithmetic Mean	1,289,533
	Coefficient Of Variation	526.53
	Mean Deviation	5,153,449
	Median	(1,291,000)
	Standard Deviation	6,789,826
	Sample Variance	46.1T
	Range	24.5M
	R-Value	0.59
	Mean Square Error	32.2T
	R-Squared	0.35
	Significance	0.02
	Slope	899,739
	Total Sum of Squares	645.4T

Aligos Gross Profit History

	2024	13.1 M
	2023	12.5 M
	2022	13.9 M
	2021	4.4 M
	2020	-10.5 M
	2019	-2.3 M

Other Fundumenentals of Aligos Therapeutics

Gross Profit Margin

Aligos Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Capital Surpluse
Total Assets		0.91	0.9	0.54	-0.97	-0.6	0.25	-0.81	-0.61	0.91	1.0	0.98	0.76	0.47	-0.25	0.4
Total Stockholder Equity	0.91		1.0	0.48	-0.93	-0.7	0.21	-0.79	-0.88	1.0	0.93	0.89	0.84	0.5	-0.42	0.55
Net Tangible Assets	0.9	1.0		0.44	-0.93	-0.73	0.18	-0.81	-0.89	1.0	0.92	0.88	0.86	0.56	-0.45	0.6
Current Deferred Revenue	0.54	0.48	0.44		-0.43	-0.16	0.63	-0.16	-0.23	0.48	0.52	0.47	0.43	-0.05	0.08	0.0
Net Debt	-0.97	-0.93	-0.93	-0.43		0.73	-0.2	0.9	0.68	-0.93	-0.98	-0.96	-0.86	-0.65	0.41	-0.57
Retained Earnings	-0.6	-0.7	-0.73	-0.16	0.73		-0.38	0.9	0.71	-0.7	-0.62	-0.52	-0.94	-0.86	0.9	-0.95
Accounts Payable	0.25	0.21	0.18	0.63	-0.2	-0.38		-0.15	-0.16	0.21	0.24	0.17	0.41	0.04	-0.43	0.2
Short Term Investments	-0.81	-0.79	-0.81	-0.16	0.9	0.9	-0.15		0.64	-0.79	-0.81	-0.75	-0.9	-0.84	0.65	-0.82
Total Liab	-0.61	-0.88	-0.89	-0.23	0.68	0.71	-0.16	0.64		-0.88	-0.66	-0.59	-0.76	-0.46	0.59	-0.65
Net Invested Capital	0.91	1.0	1.0	0.48	-0.93	-0.7	0.21	-0.79	-0.88		0.93	0.89	0.84	0.5	-0.42	0.55
Total Current Assets	1.0	0.93	0.92	0.52	-0.98	-0.62	0.24	-0.81	-0.66	0.93		0.99	0.78	0.49	-0.29	0.42
Net Working Capital	0.98	0.89	0.88	0.47	-0.96	-0.52	0.17	-0.75	-0.59	0.89	0.99		0.69	0.43	-0.19	0.31
Short Term Debt	0.76	0.84	0.86	0.43	-0.86	-0.94	0.41	-0.9	-0.76	0.84	0.78	0.69		0.8	-0.74	0.86
Common Stock	0.47	0.5	0.56	-0.05	-0.65	-0.86	0.04	-0.84	-0.46	0.5	0.49	0.43	0.8		-0.76	0.88
Property Plant Equipment	-0.25	-0.42	-0.45	0.08	0.41	0.9	-0.43	0.65	0.59	-0.42	-0.29	-0.19	-0.74	-0.76		-0.89
Capital Surpluse	0.4	0.55	0.6	0.0	-0.57	-0.95	0.2	-0.82	-0.65	0.55	0.42	0.31	0.86	0.88	-0.89

Click cells to compare fundamentals

About Aligos Therapeutics Financial Statements

Aligos Therapeutics shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Aligos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aligos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aligos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	12.5 M	13.1 M
Gross Profit Margin	0.80	0.84

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aligos Stock Analysis

When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC